UCB, Five Prime in discovery deal for inflammation and CNS disorders

UCB Group (Euronext:UCB) and Five Prime Therapeutics Inc. (South San Francisco, Calif.) partnered to discover drug targets and therapeutics for fibrosis-related inflammatory diseases and CNS disorders. Under the deal, UCB and Five Prime will design assays to screen Five Prime's library of functional secreted proteins and transmembrane receptor proteins. Five Prime will use the assays with its technology platforms to identify targets and candidates for up to five programs selected by the companies. UCB has an exclusive option to license worldwide rights to targets discovered under the deal and would be responsible for development and commercialization of selected targets. ...